EyePoint at TD Cowen Conference: DURAVYU’s Market Potential

EyePoint Pharmaceuticals (NASDAQ:EYPT) presented at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, outlining the strategic potential of its DURAVYU drug candidate for treating diabetic macular edema and wet age-related macular degeneration amid challenges of market underappreciation. The biopharmaceutical company detailed the clinical trial data for DURAVYU, emphasizing its innovative approach to treating these serious eye conditions that affect millions of people worldwide. During the presentation, EyePoint's management highlighted the unique mechanisms of DURAVYU and how it differentiates from existing treatments in the ophthalmology market. The conference appearance comes at a critical time as EyePoint seeks to build investor confidence and demonstrate the commercial viability of its pipeline products. Management specifically addressed concerns about market recognition, outlining strategies to educate stakeholders about DURAVYU's potential benefits and the science behind its novel delivery system. The company's presentation concluded with a roadmap for future development, including anticipated regulatory milestones and potential market entry strategies for DURAVYU in both the United States and international markets.